This article was originally published in Start Up
Corgentech Inc. aims to avoid the problems that have thwarted viral and liposome-based gene delivery with a pressure-mediated delivery system. Its payload is decoys of transcription factors, the proteins that regulate gene expression. Corgentech's TF decoys are designed to bind with transcription factors, preventing normal DNA from burrowing in and activating its target gene.
You may also be interested in...
In heart valve surgery, there have been no home runs yet among the numerous efforts to improve the durability of tissue valves. ValveXchange Inc. has a different solution: improving the way that worn valves are replaced. The start-up is developing a tissue valve with exchangeable leaflets that can be exchanged either percutaneously or via minimally invasive techniques. By focusing on the replacement procedure, ValveXchange aims to make bioprosthetic valves more attractive to the increasingly younger patient population for whom its faster and safer exchange technology will provide a lifetime solution.
Avontec GMBH is a German start up company focused on developing drugs for inflammatory diseases by interfering with transcription factors. Founded in August 2001, the firm has two drugs entering Phase I trials based on its decoy oligonucleotide technology and an agreement with Biotronik GMBH to develop next-generation drug-eluting stents.
By marrying gene therapy with medical device technology, Sweden's Xenerate AB believes it can make implantable vascular devices--artificial grafts and stents--capable of endothelialization, thus improving their biocompatibility and reducing the incidence of intimal hyperplasia, restenosis and other adverse effects.